Product Description
Mechanisms of Action: FGFR Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Kaken Pharmaceutical
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Diabetic Foot|Periodontal Attachment Loss|Periodontitis|Alveolar Bone Loss
Phase 2: Periodontitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00199290 |
KCB-1D-02 | P2 |
Completed |
Periodontitis |
2007-07-01 |
2019-03-21 |
Treatments |
|
JapicCTI-050033 |
JapicCTI-050033 | P2 |
Unknown |
Periodontitis |
None |
|||
2010-021014-33 |
The TRAfermin in Neuropathic diabetic foot ulcer Study - southern Europe. The TRANS-North study | P3 |
Completed |
Diabetic Foot |
2013-02-06 |
2022-03-13 |
Treatments |
|
2010-021015-16 |
The TRAfermin in Neuropathic diabetic foot ulcer Study - northern Europe. The TRANS-North study | P3 |
Terminated |
Diabetic Foot |
2012-09-30 |
2022-03-13 |
Treatments |
|
NCT01217476 |
TRANS-North | P3 |
Completed |
Diabetic Foot |
2012-05-01 |
2019-03-19 |
Treatments |
|
NCT01217463 |
TRANS-South | P3 |
Completed |
Diabetic Foot |
2012-03-01 |
2019-03-19 |
Treatments |
|
NCT01015404 |
KCB-1D-04 | P3 |
Completed |
Periodontitis |
2010-03-01 |
2019-03-19 |
Treatments |
|
NCT00734708 |
Trafermin | P3 |
Completed |
Periodontitis|Alveolar Bone Loss|Periodontal Attachment Loss |
2010-03-01 |
2019-03-18 |
Treatments |